Protocol

Anticoagulants, Antiplatelets, and Thrombolytics

Volume 93 of the series Methods In Molecular Medicine™ pp 21-34

Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis

  • Owen J. T. McCartyAffiliated withDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University
  • , James P. AbulenciaAffiliated withDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University
  • , Shaker A. MousaAffiliated withAlbany College of Pharmacy
  • , Konstantinos KonstantopoulosAffiliated withDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Intravascular thrombosis is one of the most frequent pathological events that affects mankind, and a major cause of morbidity and mortality in developed countries. There is abundant evidence suggesting that platelets play a pivotal role in the pathogenesis of arterial thrombotic disorders, including unstable angina (UA), myocardial infarction (MI), and stroke (13). The underlying pathophysiological mechanism of these processes has been recognized as the disruption or erosion of a vulnerable atherosclerotic plaque, leading to local platelet adhesion and subsequent formation of partially or completely occlusive platelet thrombi.